Nothing Special   »   [go: up one dir, main page]

EA201001821A1 - Производные триазола, полезные для лечения заболеваний - Google Patents

Производные триазола, полезные для лечения заболеваний

Info

Publication number
EA201001821A1
EA201001821A1 EA201001821A EA201001821A EA201001821A1 EA 201001821 A1 EA201001821 A1 EA 201001821A1 EA 201001821 A EA201001821 A EA 201001821A EA 201001821 A EA201001821 A EA 201001821A EA 201001821 A1 EA201001821 A1 EA 201001821A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
treatment
triazole derivatives
derivatives useful
compounds
Prior art date
Application number
EA201001821A
Other languages
English (en)
Inventor
Лин Говард Джонс
Даниель Фрэнсис Робертс
Росс Синклер Стрэнг
Original Assignee
Пфайзер Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Лимитед filed Critical Пфайзер Лимитед
Publication of EA201001821A1 publication Critical patent/EA201001821A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к соединениям формулы (1)и к способам их получения, промежуточным соединениям, используемым в их получении, содержащим их композициям и применению таких производных. Соединения по настоящему изобретению полезны при различных заболеваниях, расстройствах и состояниях, в частности воспалительных, аллергических и респираторных заболеваниях, расстройствах и состояниях.
EA201001821A 2008-07-11 2009-07-09 Производные триазола, полезные для лечения заболеваний EA201001821A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7983708P 2008-07-11 2008-07-11
PCT/IB2009/052986 WO2010004517A1 (en) 2008-07-11 2009-07-09 Triazole derivatives useful for the treatment of diseases

Publications (1)

Publication Number Publication Date
EA201001821A1 true EA201001821A1 (ru) 2011-08-30

Family

ID=41078162

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001821A EA201001821A1 (ru) 2008-07-11 2009-07-09 Производные триазола, полезные для лечения заболеваний

Country Status (30)

Country Link
US (1) US8263623B2 (ru)
EP (1) EP2300443B1 (ru)
JP (1) JP5608162B2 (ru)
KR (1) KR101235962B1 (ru)
CN (1) CN102089290B (ru)
AP (1) AP2010005508A0 (ru)
AR (1) AR072488A1 (ru)
AU (1) AU2009269610B2 (ru)
BR (1) BRPI0915897A2 (ru)
CA (1) CA2726686C (ru)
CO (1) CO6321248A2 (ru)
CR (1) CR11818A (ru)
DK (1) DK2300443T3 (ru)
DO (1) DOP2011000010A (ru)
EA (1) EA201001821A1 (ru)
EC (1) ECSP11010754A (ru)
ES (1) ES2398428T3 (ru)
HK (1) HK1154382A1 (ru)
IL (1) IL209730A (ru)
MA (1) MA32466B1 (ru)
MX (1) MX2011000352A (ru)
NI (1) NI201100006A (ru)
NZ (1) NZ589613A (ru)
PE (1) PE20110151A1 (ru)
SV (1) SV2011003802A (ru)
TW (1) TW201006822A (ru)
UA (1) UA99524C2 (ru)
UY (1) UY31976A (ru)
WO (1) WO2010004517A1 (ru)
ZA (1) ZA201100534B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
NZ603136A (en) 2010-05-10 2014-11-28 Gilead Sciences Inc Bifunctional quinoline derivatives
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
KR101840852B1 (ko) 2011-10-10 2018-03-22 삼성전자주식회사 모바일 장치의 표면 온도 관리 방법 및 멀티칩 패키지의 메모리 열관리 방법
KR101857529B1 (ko) 2011-11-08 2018-05-15 삼성전자주식회사 비휘발성 메모리 장치 및 그것의 구동 방법
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
DE102012111829B4 (de) 2011-12-06 2024-10-10 Samsung Electronics Co., Ltd. Speichersysteme und Blockkopierverfahren davon
KR101859646B1 (ko) 2011-12-16 2018-05-18 삼성전자주식회사 보안 데이터를 보호하는 메모리 장치 및 보안 데이터를 이용한 데이터 보호 방법
DE102013100596B4 (de) 2012-01-27 2023-09-07 Samsung Electronics Co. Ltd. Nichtflüchtiges Speichersystem mit Programmier- und Löschverfahren und Blockverwaltungsverfahren
KR101903440B1 (ko) 2012-02-21 2018-10-02 삼성전자주식회사 비휘발성 메모리 장치 및 그것의 접지 선택 트랜지스터의 문턱전압 조절 방법
DE102013105356A1 (de) 2012-05-29 2013-12-05 Samsung Electronics Co., Ltd. Verfahren zum Betreiben von nichtflüchtigen Speichervorrichtungen, die effiziente Fehlererkennung unterstützen
KR101996004B1 (ko) 2012-05-29 2019-07-03 삼성전자주식회사 비휘발성 메모리 장치의 프로그램 방법 및 그것의 메모리 시스템
KR102000634B1 (ko) 2012-06-07 2019-07-16 삼성전자주식회사 비휘발성 메모리 장치 및 그것의 소거 방법
KR102025263B1 (ko) 2012-10-05 2019-09-25 삼성전자주식회사 메모리 시스템 및 그것의 읽기 교정 방법
KR102025251B1 (ko) 2012-10-31 2019-09-25 삼성전자주식회사 메모리 시스템 및 그것의 프로그램 방법
BR112015013628A2 (pt) 2012-12-18 2017-07-11 Almirall Sa derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
KR102068342B1 (ko) 2013-03-07 2020-01-20 삼성전자주식회사 메모리 제어기 및 그것을 포함하는 메모리 시스템
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
KR102187643B1 (ko) 2013-12-04 2020-12-08 삼성전자주식회사 메모리 시스템 및 그것을 포함하는 유저 장치
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
AU2017376363B2 (en) 2016-12-14 2020-02-06 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quaternary ammonium salt structure
CN107194205B (zh) * 2017-05-31 2020-11-24 浙江大学 具有杀菌活性的jak2激酶抑制剂及其虚拟筛选方法
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0823423B1 (en) 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
GB9603755D0 (en) 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
HUP0303524A3 (en) 2000-12-28 2008-03-28 Almirall Ag Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same and their use
DE10200943A1 (de) 2002-01-12 2003-07-24 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Scopinestern
AU2002353286A1 (en) 2002-12-10 2004-06-30 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
CN101239970B (zh) * 2003-02-14 2011-07-20 施万制药 联苯衍生物
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
EP1615881A2 (en) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1626970B1 (en) 2003-05-28 2009-07-08 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
CA2553293C (en) 2004-01-22 2010-12-14 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
BRPI0507877A (pt) 2004-03-23 2007-07-24 Pfizer derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
US7569586B2 (en) * 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200745084A (en) * 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
WO2008023157A1 (en) 2006-08-21 2008-02-28 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as m3-receptor modulators

Also Published As

Publication number Publication date
MX2011000352A (es) 2011-02-22
NZ589613A (en) 2012-06-29
DK2300443T3 (da) 2013-02-18
EP2300443A1 (en) 2011-03-30
KR20110018423A (ko) 2011-02-23
SV2011003802A (es) 2011-03-23
CN102089290B (zh) 2013-09-04
PE20110151A1 (es) 2011-03-05
WO2010004517A1 (en) 2010-01-14
TW201006822A (en) 2010-02-16
EP2300443B1 (en) 2012-12-12
CO6321248A2 (es) 2011-09-20
CA2726686C (en) 2014-03-11
UA99524C2 (ru) 2012-08-27
IL209730A (en) 2013-11-28
NI201100006A (es) 2011-07-20
CA2726686A1 (en) 2010-01-14
ECSP11010754A (es) 2011-02-28
AU2009269610B2 (en) 2012-02-02
CR11818A (es) 2011-01-14
JP5608162B2 (ja) 2014-10-15
IL209730A0 (en) 2011-02-28
BRPI0915897A2 (pt) 2015-11-03
AR072488A1 (es) 2010-09-01
AU2009269610A1 (en) 2010-01-14
UY31976A (es) 2010-02-26
DOP2011000010A (es) 2011-01-31
MA32466B1 (fr) 2011-07-03
JP2011527672A (ja) 2011-11-04
KR101235962B1 (ko) 2013-02-21
ZA201100534B (en) 2011-10-26
US20100010040A1 (en) 2010-01-14
AP2010005508A0 (en) 2010-12-31
CN102089290A (zh) 2011-06-08
HK1154382A1 (en) 2012-04-20
ES2398428T3 (es) 2013-03-19
US8263623B2 (en) 2012-09-11

Similar Documents

Publication Publication Date Title
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
EA200870282A1 (ru) Производные амина
EA201270575A1 (ru) Соединения
MY139690A (en) Sulfonamide derivatives for the treatment of diseases.
EA200601223A1 (ru) Производные сульфонамида для лечения заболеваний
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
EA200900337A1 (ru) Сульфонамидные производные в качестве адренергических агонистов и мускариновых антагонистов
MXPA05009304A (es) Derivados de indol utiles para el tratamiento de enfermedades.
TW200607506A (en) Tetrahydronaphthyridine derivatives
EA201000797A1 (ru) Аминотриазолы в качестве ингибиторов pi3k
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX2012012328A (es) Compuestos pirazol como inhibidores de jak.
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA200501399A1 (ru) Производные бензопирана, которые могут использоваться при лечении воспалительных заболеваний
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
TW200505865A (en) Compounds useful for the treatment of diseases
EA200601462A1 (ru) Соединения для лечения заболеваний
ATE440836T1 (de) Verbindungen
GB0609897D0 (en) Compounds
EA200601510A1 (ru) Производные фенилэтаноламина в качестве бета-2-агонистов
GB0407025D0 (en) Novel compounds
ATE525370T1 (de) Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten
EA200970422A1 (ru) Аналоги пиразола